June 24 - Xingqi eye medicine shares plunged, intraday at one point down more than 19%. Xingqi Ophthalmology closed down 16.76 percent at 136.02 yuan per share, with a total market value of 11.983 billion yuan.
On the news, there are market rumors, The blockbuster product of Xingqi Eye medicine atropine (eye drops) will be limited by Internet hospitals. According to kEChuang Board Daily reported, xingqi ophthalmology related people said in response to this, it has not heard of the restriction of the issuance of atropine rumors, the company's production and operation is normal.
It has been reported that low concentrations of atropine are effective in delaying myopia in young people, but the drug has been manufactured as a hospital preparation because of doubts about its safety and side effects. At present, Xingqi Eye Hospital, the holding subsidiary of Xingqi Eye Medicine, is actively promoting the clinical research and development of low-concentration atropine project.
Reports also said the low-concentration atropine eye drops had not yet been officially approved for sale, but were being sold through Xingqi Eye Hospital, which has Internet hospital qualifications. At the same time, the atropine eye drops sold by virtue of the hospital preparation qualification have become the performance pillar of Xingqi ophthalmic medicine.
Data show that the main business of Xingqi ophthalmic drugs is the research and development, production and sales of ophthalmic drugs, the main products are ophthalmic prescription drugs, representative products include "sogajie", "Diyou", "Difei", "Ziyang", "Dicorro" and other ophthalmic preparations. (Liu Town)